

Termination of Collaborative Research and License Agreement with Legend Biotech, Inc.

Tokyo, Japan (February 18, 2022) - Noile-Immune Biotech Inc. (“Noile-Immune”) today announced that Noile-Immune and Legend Biotech USA, Inc. (“Legend Biotech”) have mutually agreed to terminate their Collaborative Research and License Agreement dated as of April 27, 2020 (as amended, the “Agreement”), effective on January 28, 2022 as the parties were not able to mutually agree upon an antigen target to be selected for further research.